287 related articles for article (PubMed ID: 31141829)
61. Trametinib therapy for children with neurofibromatosis type 1 and life-threatening plexiform neurofibroma or treatment-refractory low-grade glioma.
Ronsley R; Hounjet CD; Cheng S; Rassekh SR; Duncan WJ; Dunham C; Gardiner J; Ghag A; Ludemann JP; Wensley D; Rehmus W; Sargent MA; Hukin J
Cancer Med; 2021 Jun; 10(11):3556-3564. PubMed ID: 33939292
[TBL] [Abstract][Full Text] [Related]
62. Response to everolimus of a progressive plexiform neurofibroma in Neurofibromatosis type 1.
Mateos ME; López-Laso E; Vicente J; Ortega R; Vázquez F; Pérez-Navero JL
Pediatr Int; 2020 Jul; 62(7):857-859. PubMed ID: 32027426
[No Abstract] [Full Text] [Related]
63. Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity.
Gross AM; Glassberg B; Wolters PL; Dombi E; Baldwin A; Fisher MJ; Kim A; Bornhorst M; Weiss BD; Blakeley JO; Whitcomb P; Paul SM; Steinberg SM; Venzon DJ; Martin S; Carbonell A; Heisey K; Therrien J; Kapustina O; Dufek A; Derdak J; Smith MA; Widemann BC
Neuro Oncol; 2022 Nov; 24(11):1978-1988. PubMed ID: 35467749
[TBL] [Abstract][Full Text] [Related]
64. Neurofibromatosis type 1 (NF1): diagnosis and management.
Ferner RE; Gutmann DH
Handb Clin Neurol; 2013; 115():939-55. PubMed ID: 23931823
[TBL] [Abstract][Full Text] [Related]
65. NF1 truncating mutations associated to aggressive clinical phenotype with elephantiasis neuromatosa and solid malignancies.
Ponti G; Martorana D; Pellacani G; Ruini C; Loschi P; Baccarani A; De Santis G; Pollio A; Neri TM; Mandel VD; Maiorana A; Maccio L; Maccaferri M; Tomasi A
Anticancer Res; 2014 Jun; 34(6):3021-30. PubMed ID: 24922668
[TBL] [Abstract][Full Text] [Related]
66. The role of nerve microenvironment for neurofibroma development.
Liao CP; Pradhan S; Chen Z; Patel AJ; Booker RC; Le LQ
Oncotarget; 2016 Sep; 7(38):61500-61508. PubMed ID: 27517146
[TBL] [Abstract][Full Text] [Related]
67. Massive spontaneous haemorrhage in a plexiform neurofibroma: A case report and discussion of the literature.
Miller J; Perotti V; Moore P
J Clin Neurosci; 2020 Oct; 80():229-231. PubMed ID: 33099350
[TBL] [Abstract][Full Text] [Related]
68. Selumetinib for plexiform neurofibromas in neurofibromatosis type 1: a single-institution experience.
Espírito Santo V; Passos J; Nzwalo H; Carvalho I; Santos F; Martins C; Salgado L; Silva CE; Vinhais S; Vilares M; Salgado D; Nunes S
J Neurooncol; 2020 Apr; 147(2):459-463. PubMed ID: 32108293
[TBL] [Abstract][Full Text] [Related]
69. Neurofibromatosis type 1-associated plexiform neurofibromas of the neck: topography of lesions and surgical treatment data of 69 patients.
Friedrich RE; Löhmann DM
Oral Maxillofac Surg; 2024 Mar; 28(1):393-404. PubMed ID: 37173460
[TBL] [Abstract][Full Text] [Related]
70. Selumetinib in the Treatment of Orbital Plexiform Neurofibroma: A Case Report.
Dai YL; Choi CS; Wiltsie L; Callahan AB
Ophthalmic Plast Reconstr Surg; 2023 May-Jun 01; 39(3):e75-e78. PubMed ID: 36807287
[TBL] [Abstract][Full Text] [Related]
71. Preclincial testing of sorafenib and RAD001 in the Nf(flox/flox) ;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging.
Wu J; Dombi E; Jousma E; Scott Dunn R; Lindquist D; Schnell BM; Kim MO; Kim A; Widemann BC; Cripe TP; Ratner N
Pediatr Blood Cancer; 2012 Feb; 58(2):173-80. PubMed ID: 21319287
[TBL] [Abstract][Full Text] [Related]
72. Selumetinib side effects in children treated for plexiform neurofibromas: first case reports of peripheral edema and hair color change.
Baldo F; Magnolato A; Barbi E; Bruno I
BMC Pediatr; 2021 Feb; 21(1):67. PubMed ID: 33549085
[TBL] [Abstract][Full Text] [Related]
73. Population pharmacokinetics and exposure-response of selumetinib and its N-desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas.
Schalkwijk S; Zhou L; Cohen-Rabbie S; Jain L; Freshwater T; So K; He Z; Gioni I; Tomkinson H; Vishwanathan K; Zhou D
Cancer Chemother Pharmacol; 2021 Aug; 88(2):189-202. PubMed ID: 33903938
[TBL] [Abstract][Full Text] [Related]
74. Pediatric plexiform neurofibromas: impact on morbidity and mortality in neurofibromatosis type 1.
Prada CE; Rangwala FA; Martin LJ; Lovell AM; Saal HM; Schorry EK; Hopkin RJ
J Pediatr; 2012 Mar; 160(3):461-7. PubMed ID: 21996156
[TBL] [Abstract][Full Text] [Related]
75. [Progress in diagnosis and treatment of neurofibromatosis in children].
Wang S; Li Y; Zhang J; Ni X
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2022 Jun; 36(6):477-482. PubMed ID: 35822370
[No Abstract] [Full Text] [Related]
76. Development and pilot validation of a novel disfigurement severity scale for plexiform neurofibromas in children with neurofibromatosis type 1.
John L; Singh G; Dombi E; Wolters PL; Martin S; Baldwin A; Steinberg SM; Bernstein J; Whitcomb P; Pichard DC; Dufek A; Gillespie A; Heisey K; Bornhorst M; Fisher MJ; Weiss BD; Kim A; Widemann BC; Gross AM
Clin Trials; 2024 Apr; 21(2):189-198. PubMed ID: 37877369
[TBL] [Abstract][Full Text] [Related]
77. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications.
Gottfried ON; Viskochil DH; Couldwell WT
Neurosurg Focus; 2010 Jan; 28(1):E8. PubMed ID: 20043723
[TBL] [Abstract][Full Text] [Related]
78. Germline and somatic NF1 gene mutations in plexiform neurofibromas.
Upadhyaya M; Spurlock G; Monem B; Thomas N; Friedrich RE; Kluwe L; Mautner V
Hum Mutat; 2008 Aug; 29(8):E103-11. PubMed ID: 18484666
[TBL] [Abstract][Full Text] [Related]
79. Efficacy and safety profile of selumetinib in symptomatic inoperable plexiform neurofibromas.
Sharawat IK; Panda PK; Sihag RK; Panda P; Dawman L
J Neurosurg Sci; 2022 Dec; 66(6):501-510. PubMed ID: 35301838
[TBL] [Abstract][Full Text] [Related]
80. Sirolimus improves pain in NF1 patients with severe plexiform neurofibromas.
Hua C; Zehou O; Ducassou S; Minard-Colin V; Hamel-Teillac D; Wolkenstein P; Valeyrie-Allanore L
Pediatrics; 2014 Jun; 133(6):e1792-7. PubMed ID: 24864177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
